{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:42Z","timestamp":1787164722728,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016198","name":"Idorsia Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.euroneuro.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T23:08:34Z","timestamp":1622848114000},"page":"90-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects"],"prefix":"10.1016","volume":"51","author":[{"given":"Benjamin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Kornberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2021.05.005_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/00207459008994241","article-title":"Subjective and objective sleepiness in the active individual","volume":"52","author":"\u00c5kerstedt","year":"1990","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-003-0591-5","article-title":"Effects on postural oscillation and memory functions of a single dose of zolpidem 5mg, zopiclone 3.75mg and lormetazepam 1mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo","volume":"59","author":"Allain","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0003","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0004","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2165\/00003088-199631060-00004","article-title":"Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors","volume":"31","author":"Baumann","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","article-title":"The use of analogue scales in rating subjective feelings","volume":"47","author":"Bond","year":"1974","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","article-title":"Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies","volume":"75","author":"Boof","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0007","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/cmdc.202000453","article-title":"The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders","volume":"15","author":"Boss","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0006-3223(95)00188-3","article-title":"Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults","volume":"39","author":"Breslau","year":"1996","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0269881118822258","article-title":"The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia","volume":"33","author":"Brooks","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0010","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269881106074062","article-title":"A single dose of citalopram increases fear recognition in healthy subjects","volume":"21","author":"Browning","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0011","unstructured":"CelexaUSPI, 2011 . Celexa\u00ae US Package Insert. United States Food and Drug Administration full prescribing information [accessed on 12 January 2021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/1998\/20822lbl.pdf."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0012","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/bcp.13204","article-title":"Pharmacodynamic response profiles of anxiolytic and sedative drugs","volume":"83","author":"Chen","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0013","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0893-133X(02)00294-4","article-title":"Early changes in prefrontal activity characterize clinical responders to antidepressants","volume":"27","author":"Cook","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0014","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.euroneuro.2014.05.002","article-title":"Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine","volume":"24","author":"Cruz","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2001.01308.x","article-title":"Biomarkers for the effects of antipsychotic drugs in healthy volunteers","volume":"51","author":"de Visser","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0017","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3758\/BF03200977","article-title":"Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations","volume":"17","author":"Dinges","year":"1985","journal-title":"Behav. Res. Methods Instrum. Comput."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0018","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2125.2005.02342.x","article-title":"Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects","volume":"59","author":"Dumont","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0019","unstructured":"EMA, 2011. European medicines agency, committee for medicinal products for human use (CHMP): guideline on medicinal products for the treatment of insomnia, EMA\/CHMP\/16274\/2009 [accessed October 2019]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-medicinal-products-treatment-insomnia_en.pdf."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1099-1077(199703\/04)12:2<119::AID-HUP847>3.0.CO;2-W","article-title":"Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance","volume":"12","author":"Fairweather","year":"1997","journal-title":"Hum. Psychopharm. Clin."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.biopsych.2006.01.016","article-title":"Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder","volume":"59","author":"Fava","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0022","unstructured":"FDA, 1977. U.S. Food and Drug Administration: guidelines for the clinical evaluation of hypnotic compounds. [accessed October 2019]. Available from: https:\/\/www.fda.gov\/media\/71609\/download."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0023","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.1989.03430110069030","article-title":"Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?","volume":"262","author":"Ford","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0024","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2016.07.004","article-title":"Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery","volume":"20","author":"Groeneveld","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0025","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00213-002-1151-x","article-title":"Acute administration of citalopram facilitates memory consolidation in healthy volunteers","volume":"163","author":"Harmer","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0026","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/sj.npp.1300004","article-title":"Acute SSRI administration affects the processing of social cues in healthy volunteers","volume":"28","author":"Harmer","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0027","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF02190245","article-title":"Prevalence and treatment of insomnia in general practice. A longitudinal study","volume":"242","author":"Hohagen","year":"1993","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2021.05.005_bib0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199403001-00004","article-title":"Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)","volume":"9 Suppl","author":"Hyttel","year":"1994","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0029","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","article-title":"Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing","volume":"38","author":"Jaeger","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/026988110201600308","article-title":"Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men","volume":"16","author":"Jezova","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0031","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4088\/JCP.v61n1202","article-title":"Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials","volume":"61","author":"Keller","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/08039480903511381","article-title":"The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review","volume":"64","author":"Knorr","year":"2010","journal-title":"Nord J Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0773.1981.tb01587.x","article-title":"The kinetics of citalopram: single and multiple dose studies in man","volume":"48","author":"Kragh-Sorensen","year":"1981","journal-title":"Acta. Pharmacol. Toxicol. (Copenh)."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0034","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00606656","article-title":"The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects","volume":"31","author":"Lader","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.159.1.122","article-title":"Changes in brain function of depressed subjects during treatment with placebo","volume":"159","author":"Leuchter","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0036","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1113\/jphysiol.2013.256271","article-title":"Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats","volume":"591","author":"Li","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0037","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0038","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2165\/00003495-199141030-00008","article-title":"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness","volume":"41","author":"Milne","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0039","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1371\/journal.pmed.0030240","article-title":"Do antidepressants cure or create abnormal brain states?","volume":"3","author":"Moncrieff","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/cpt.1046","article-title":"Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study","volume":"104","author":"Muehlan","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0041","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","article-title":"Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration","volume":"29","author":"Muehlan","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0042","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/1389200220666190206141814","article-title":"Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer\/accelerator mass spectrometry","volume":"20","author":"Muehlan","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0043","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/0269881119882854","article-title":"Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration","volume":"34","author":"Muehlan","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0044","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S1461145708009164","article-title":"Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers","volume":"12","author":"Murphy","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0046","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0047","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4088\/JCP.v66n0201","article-title":"Is there a delay in the antidepressant effect? A meta-analysis","volume":"66","author":"Posternak","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0048","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/epi.14732","article-title":"First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker","volume":"60","author":"Richard","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0049","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881105048887","article-title":"Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment","volume":"19","author":"Riedel","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0050","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2125.2002.t01-3-01714.x","article-title":"REM sleep reduction as a biomarker for the effects of antidepressants in healthy volunteers","volume":"54","author":"Rijnbeek","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0051","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0052","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/FPC.0b013e328346063f","article-title":"PharmGKB summary: citalopram pharmacokinetics pathway","volume":"21","author":"Sangkuhl","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0053","first-page":"21","article-title":"Daridorexant, a novel dual orexin receptor antagonist, does not prolong the QT interval duration following bedtime dosing; Results from a thorough QT study, ASCPT 2021 Annual Meeting, PI-053","volume":"109","author":"Schilling","year":"2021","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0054","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00213-001-0993-y","article-title":"Modulation of the Critical Flicker Fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes","volume":"160","author":"Schmitt","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0055","series-title":"Arzneiverordnungs-Report 2019: Aktuelle Daten, Kosten, Trends und Kommentare","author":"Schwabe","year":"2019"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0056","series-title":"Focus on: Antidepressant prescribing. Trends in the Prescribing of Antidepressants in Primary care. Research report","author":"Spence","year":"2014"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0057","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-199920030-00007","article-title":"Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system","volume":"20","author":"Spigset","year":"1999","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0058","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update","volume":"30","author":"Spina","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0059","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.smrv.2009.09.003","article-title":"Comorbidity of insomnia and depression","volume":"14","author":"Staner","year":"2010","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/sleep\/29.11.1391","article-title":"Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years","volume":"29","author":"Stewart","year":"2006","journal-title":"Sleep"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0061","series-title":"27th Annual Meeting of the Associated Professional Sleep Societies, LLC, SLEEP 2013. Baltimore, MD, United States","article-title":"Phase 1 safety, pharmacokinetics, and pharmacodynamics of the orexin receptor antagonist suvorexant administered with alcohol or paroxetine","author":"Sun","year":"2013"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0062","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0063","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/clpt.1991.122","article-title":"A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers","volume":"50","author":"van Steveninck","year":"1991","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0064","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2125.1996.38514.x","article-title":"Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol","volume":"41","author":"van Steveninck","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/026988119901300102","article-title":"The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation","volume":"13","author":"van Steveninck","year":"1999","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0066","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00213-011-2484-0","article-title":"Predicting psychopharmacological drug effects on actual driving performance (SDLP) from psychometric tests measuring driving-related skills","volume":"220","author":"Verster","year":"2012","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0067","article-title":"Manual for the Wechsler adult intelligence scale","author":"Wechsler","year":"1955","journal-title":"Psychological Corp"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0068","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2012.10.021","article-title":"Orexin A regulates cardiovascular responses in stress-induced hypertensive rats","volume":"67","author":"Xiao","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0069","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/dmd.31.10.1255","article-title":"Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19","volume":"31","author":"Yu","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0070","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2021.05.005_bib0071","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/1440-1681.13370","article-title":"The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin","volume":"47","author":"Zenklusen","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiolog."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2100225X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2100225X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:01:27Z","timestamp":1760378487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2100225X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":71,"alternative-id":["S0924977X2100225X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.05.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}